Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
May 30, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 07:30 ET
|
Wave Life Sciences USA, Inc.
RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected...
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
May 09, 2024 07:00 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
May 02, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
April 30, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
April 23, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation...
Wave Life Sciences to Present at Upcoming Investor Conferences
March 27, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024 07:30 ET
|
Wave Life Sciences USA, Inc.
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and...